Alvotech (ALVO)
Market Cap | 3.42B |
Revenue (ttm) | 114.39M |
Net Income (ttm) | -494.28M |
Shares Out | 279.57M |
EPS (ttm) | -2.08 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 168,473 |
Open | 12.35 |
Previous Close | 12.36 |
Day's Range | 12.15 - 12.40 |
52-Week Range | 8.03 - 18.00 |
Beta | -0.05 |
Analysts | Buy |
Price Target | 16.00 (+30.72%) |
Earnings Date | May 21, 2024 |
About ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond... [Read more]
Full Company ProfileFinancial Performance
In 2023, Alvotech's revenue was $93.38 million, an increase of 9.84% compared to the previous year's $85.02 million. Losses were -$551.73 million, 7.43% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ALVO stock is "Buy." The 12-month stock price forecast is $16.0, which is an increase of 30.72% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/j/m/press17-2505696.jpg)
Alvotech Issues New Shares to Holders of Convertible Bonds
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
![](https://cdn.snapi.dev/images/v1/6/l/press10-2504185.jpg)
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
![](https://cdn.snapi.dev/images/v1/f/g/press11-2496765.jpg)
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
REYKJAVIK, Iceland , June 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
![](https://cdn.snapi.dev/images/v1/o/z/press10-2483693.jpg)
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
REYKJAVIK, Iceland and LONDON, June 18, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
![](https://cdn.snapi.dev/images/v1/h/m/press20-2472631.jpg)
Alvotech and STADA add to Strategic Alliance through Denosumab Partnership
Alvotech and STADA are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover AVT03, a clinical-stage biosimilar candidate...
![](https://cdn.snapi.dev/images/v1/w/e/press2-2472633.jpg)
Alvotech and STADA add to strategic alliance through denosumab partnership
REYKJAVIK, Iceland and BAD VILBEL, Germany, June 11, 2024 (GLOBE NEWSWIRE) -- Alvotech and STADA are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by ext...
![](https://cdn.snapi.dev/images/v1/q/p/press7-2467694.jpg)
Alvotech Announces Strategic Refinancing Agreement
REYKJAVIK, Iceland, June 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
![](https://cdn.snapi.dev/images/v1/w/q/press20-2451414.jpg)
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
REYKJAVIK, Iceland, May 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, a...
![](https://cdn.snapi.dev/images/v1/w/h/press3-2442550.jpg)
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
REYKJAVIK, Iceland, May 21, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for pat...
![](https://cdn.snapi.dev/images/v1/f/p/press19-2441277.jpg)
Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
HYDERABAD, INDIA & REYKJAVIK, ICELAND — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), a...
![](https://cdn.snapi.dev/images/v1/z/c/press7-2440696.jpg)
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
PARSIPPANY, N.J. & REYKJAVÍK, Iceland--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced...
![](https://cdn.snapi.dev/images/v1/c/g/press6-2440694.jpg)
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
REYKJAVIK, ICELAND & PARSIPPANY, NJ — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability...
![](https://cdn.snapi.dev/images/v1/c/x/press17-2432236.jpg)
Alvotech S.A. Annual General Meeting to be held June 7, 2024
The Annual General Meeting of Alvotech S.A. will be held on Friday June 7, 2024, at 09.00 a.m. CEST at the premises of Arendt & Medernach S.A. at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand D...
![](https://cdn.snapi.dev/images/v1/i/q/conf5-2426742.jpg)
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, an...
![](https://cdn.snapi.dev/images/v1/r/g/press3-2405623.jpg)
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be pa...
![](https://cdn.snapi.dev/images/v1/e/c/press2-2398944.jpg)
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
REYKJAVIK, Iceland & PARSIPPANY, N.J. & TEL AVIV, Israel--(BUSINESS WIRE)--Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
![](https://cdn.snapi.dev/images/v1/w/a/press7-2387328.jpg)
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a confir...
![](https://cdn.snapi.dev/images/v1/s/w/press13-2380173.jpg)
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
REYKJAVIK, Iceland, April 19, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
![](https://cdn.snapi.dev/images/v1/u/a/press9-2374753.jpg)
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
REYKJAVIK, Iceland & PARSIPPANY, N.J.--(BUSINESS WIRE)--Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced...
![](https://cdn.snapi.dev/images/v1/z/7/press5-2353952.jpg)
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
![](https://cdn.snapi.dev/images/v1/n/c/press9-2338178.jpg)
Alvotech Announces Increase in Number of Own Shares
REYKJAVIK, Iceland, March 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for pat...
![](https://cdn.snapi.dev/images/v1/5/m/press14-2334037.jpg)
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for...
![](https://cdn.snapi.dev/images/v1/d/m/conf16-2309508.jpg)
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results ...
![](https://cdn.snapi.dev/images/v1/a/r/press2-2302239.jpg)
Alvotech Appoints Interim Chief Quality Officer
REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
![](https://cdn.snapi.dev/images/v1/q/p/press8-2292817.jpg)
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has accepted an offer from inv...